#blinatumomab
LightNews LightNews
nejm.org
Presented at #ASH24:

The addition of blinatumomab after induction chemotherapy in children with standard-risk disease of average or high risk of relapse significantly improved disease-free survival.

Full AALL1731 trial results: nej.md/49CVkc1

#medsky
December 7, 2024 at 3:34 PM
oncodaily.bsky.social
Up-front Blinatumomab Improves MRD Clearance and Outcome in Adult Ph− B-lineage ALL - Talha Badar
@talhabadarmd.bsky.social

oncodaily.com/science/blin...

#Cancer #CancerResearch #Medicine #Health #Leukemia #BloodCancer #Oncology #OncoDaily
Talha Badar: Up-front Blinatumomab Improves MRD Clearance and Outcome in Adult Ph− B-lineage ALL - OncoDaily
Talha Badar: Up-front Blinatumomab Improves MRD Clearance and Outcome in Adult Ph− B-lineage ALL / blinatumomab, cancer, fight against cancer, GIMEMA LAL2317,
oncodaily.com
March 1, 2025 at 9:46 PM
doconco.bsky.social
sogenannte (BiTEs), die aus zwei unterschiedlichen monoklonalen Antikörpern zusammengesetzt sind und damit z. B. im Fall von Blinatumomab T-Zellen (über CD3) und Leukämiezellen (CD19 bei ALL) zusammenbringen und damit zur Zerstörung von Leukämiezellen führen
Wirkungsweise eines bispezifischen Antikörpers.
January 8, 2025 at 6:27 AM
nejm.org
Blinatumomab has been shown to improve outcomes in children with relapsed B-cell ALL, but the effects in children with newly diagnosed disease have been unclear. Research findings are summarized in a new Quick Take video. youtu.be/oADeOZpNYY8

#MedSky #Hematology
Blinatumomab in B-Cell Acute Lymphoblastic Leukemia | NEJM
YouTube video by NEJM Group
youtu.be
February 28, 2025 at 8:11 PM
davidbflower.bsky.social
Exciting new cancer drug kinder than chemotherapy. 🧪 www.bbc.co.uk/news/health-...
Exciting new cancer drug kinder than chemotherapy
Arthur, 11, was one of the first in the UK to try blinatumomab, for his type of blood cancer.
www.bbc.co.uk
January 17, 2024 at 3:23 AM
scientistswanda.bsky.social
Blinatumomab is one of the most precise immune‑engineering tools in modern oncology. It physically links T-cells to CD19+ leukemia cells to force targeted killing. I break down this mechanism as we enter Childhood Cancer Awareness Month.
youtu.be/H3vJlqIGKYU
How does Blinatumomab (Blincyto) Work?
YouTube video by Dr. Rob Swanda
youtu.be
September 1, 2026 at 9:24 PM
pedshemedoc.bsky.social
Truly thrilling & inspiring to see the #ASH24 plenary presentation by Rachel Rau on Blinatumomab in children with SR-B-ALL - amazing collaborative work through COG making real improvements in the care of children with leukemia❤️👏❤️ #PHO @ash-hematology.bsky.social
December 8, 2024 at 10:34 PM
natrevclinonc.nature.com
Benefit with post-consolidation blinatumomab in newly diagnosed high-risk B-ALL
Nature Reviews Clinical Oncology, Published online: 01 October 2026; doi:10.1038/s41571-026-01214-2Benefit with post-consolidation blinatumomab in newly diagnosed high-risk B-ALL
dlvr.it
October 1, 2026 at 5:27 PM
johnshuntington.bsky.social
I am currently taking a drug called Blinatumomab (brand name Blincyto) for leukemia. This drug has been a major development in leukemia treatment because it's not as hard on the body as chemotherapy.

www.bbc.com/news/health-...
Exciting new cancer drug kinder than chemotherapy
Arthur, 11, was one of the first in the UK to try blinatumomab, for his type of blood cancer.
www.bbc.com
February 14, 2025 at 5:56 PM
talhabadarmd.bsky.social
🧠 CNS prophylaxis remains essential in ALL, especially as therapy becomes chemo-attenuated or chemo-free. Blinatumomab/inotuzumab do not replace CNS-directed therapy. Modern regimens often use 12–15 IT treatments, tailored to regimen and risk. #ALL #Leukemia #Hematology
September 28, 2026 at 5:00 PM
awilm.bsky.social
Actually blinatumomab is probably the bigger deal in ALL.

Commercial CART is $500k but lots of cell therapy labs are trying to develop their own in house CARs which could become much cheaper.
April 5, 2026 at 3:16 AM
nejm.org
Among children with high-risk B-cell acute lymphoblastic leukemia, two cycles of blinatumomab led to a higher 4-year event-free survival than two cycles of chemotherapy (83.0% vs. 70.3%), with a lower risk of serious infection. Full phase 3 AIEOP-BFM ALL 2017 trial results: https://nej.md/4dBfwOk
This image contains an excerpt from the Research Summary "Blinatumomab as Chemotherapy Replacement in Pediatric ALL." It includes a diagram of how Blinatumomab works as a bispecific T-cell engager directed at CD19 on B cells. Statistics are shown: 709 children, age range of <1 to 17 years. Two treatment groups are compared: Blinatumomab (N=358) and intensive chemotherapy (N=351). A prompt to read the full Research Summary at NEJM.org sits at the bottom.
September 22, 2026 at 7:00 PM
oncodaily.bsky.social
Focusing on “chemo-free” regimen for “Ph-ve” B-cell ALL - Talha Badar

@talhabadarmd.bsky.social

oncodaily.com/insight/talh...

#Blinatumomab #Cancer #ChemoFree #Chemotherapy #CNSProphylaxis #Inozutumab #Oncodaily #Oncology #Medicine #Health
Talha Badar: Focusing on "chemo-free" regimen for "Ph-ve" B-cell ALL - OncoDaily
Talha Badar: Focusing on "chemo-free" regimen for "Ph-ve" B-cell ALL / blinatumomab, cancer, chemo-free, chemotherapy, CNS prophylaxis, Inotuzumab, OncoDaily,
oncodaily.com
January 23, 2025 at 5:46 AM
nejm.org
The addition of blinatumomab after induction chemotherapy in children with standard-risk disease of average or higher risk of relapse significantly improved disease-free survival. Full AALL1731 phase 3 trial results: nej.md/49CVkc1

#MedSky #PedSky #Hematology
The New England Journal of Medicine Blinatumomab in Standard-Risk B-Cell ALL in Children A Research Summary based on Gupta S et al. | 10.1056/NEJMoa2411680 | Published on December 7, 2024 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
March 2, 2025 at 8:58 PM
scinews.bsky.social
"A new era of childhood cancer treatment" @nejm.org

Adding blinatumomab to combination chemotherapy in patients with newly diagnosed childhood standard-risk B-cell ALL of average or high risk of relapse significantly improved disease-free survival.

www.nejm.org/doi/10.1056/...
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children | NEJM
B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed B-cell ALL remains a leading cause of cancer-related death among chi...
www.nejm.org
December 10, 2024 at 8:24 AM
nejm.org
In a patient with treatment-resistant ulcerative colitis, CD19 CAR T-cell therapy led to drug-free remission and mucosal healing, suggesting that B-cell targeting may offer a novel therapeutic pathway. Read the full report: nej.md/48gcBZV

#MedSky #GastroSky
A graph showing the circulating B-cell counts before and after treatment with blinatumomab and with chimeric antigen receptor (CAR) T cells targeting CD19.
September 26, 2025 at 2:06 PM
nejm.org
A randomized trial examined whether two cycles of blinatumomab could replace two cycles of chemotherapy in children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia. Research findings from the AIEOP-BFM ALL 2017 trial are summarized in a Quick Take video. https://nej.md/4cNe3UW
A visual representation of blinatumomab, a bispecific T-cell engager targeting CD19, for children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia.
September 20, 2026 at 1:00 PM
nejm.org
Among children with high-risk B-cell acute lymphoblastic leukemia, two cycles of blinatumomab led to a higher 4-year event-free survival than two cycles of chemotherapy (83.0% vs. 70.3%), with a lower risk of serious infection. Full phase 3 AIEOP-BFM ALL 2017 trial results: https://nej.md/4dBfwOk
A graph from an Original Article published in the New England Journal of Medicine article titled "Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia." The graph shows event-free survival. The trial name, AIEOP-BFM ALL 2017, is in parentheses after the title. The NEJM identity sits at the bottom.
September 16, 2026 at 9:40 PM
bloodjournals.hematology.org
🎙️ Just published a new episode of Blood Podcast: Pathophysiology of ANKRD26-related thrombocytopenia and B-ALL recurrence after blinatumomab . Have a listen:
Pathophysiology of ANKRD26-related thrombocytopenia and B-ALL recurrence after blinatumomab
In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs....
bloodpodcast.transistor.fm
April 23, 2026 at 4:00 PM
nejm.org
Combined treatment with a tyrosine kinase inhibitor and blinatumomab has converted Ph-positive ALL, once the most deadly hematologic cancer, to a disease with long-term survival of 75 to 80%. Read the full review: nej.md/4mhBDvU

#MedSky #Hematology
Review Article Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress Robin Foà, M.D. Figure 1. Timeline for Studies of Frontline TKIs plus Intensive or Lower-Dose Chemotherapy in Adults with Ph-Positive ALL, 1997–2024.
May 14, 2025 at 9:25 PM
ryancassaday.bsky.social
Thanks to staff of #OncLiveOnAir for the chance to discuss abstracts on ALL from #ASH24. @uwmedicine.bsky.social @fredhutch.bsky.social

www.onclive.com/view/blinatu...
Blinatumomab-Based Regimens Enhance and Refine the B-ALL Treatment Paradigm: With Ryan Cassaday, MD
Ryan Cassaday, MD, discussed insights from trials investigating blinatumomab in patients with B-ALL that were reported at the 2024 ASH Annual Meeting.
www.onclive.com
January 25, 2025 at 3:49 PM
societyofhemonc.bsky.social
Deep, durable responses in relapsed/refractory B-ALL: dose-dense mini-CVD plus inotuzumab ozogamicin and blinatumomab shows promising results for a hard-to-treat population.

Read more: sohoinsider.com/news/dose-de...
#HemOnc #Leukemia
Dose-dense mini-CVD plus inotuzumab ozogamicin, blinatumomab demonstrates deep, durable responses in relapsed or refractory B-ALL
Dose-dense mini-CVD in combination with inotuzumab and blinatumomab leads to early and high overall rates of deep MRD negativity by NGS of 95% (44% post C1) with a 3-year OS rate of 80%…
sohoinsider.com
September 30, 2026 at 1:00 AM
esaintclair.bsky.social
Big congrats to Dr Rachel Rau looking at #blinatumomab in kids. Adding it into standard #chemo significantly cut relapses and increased disease free survival. She mentioned the data monitoring board suggested a stop to randomization for efficacy. #ASH24 #ASH2024 🧪
December 8, 2024 at 10:50 PM
medicine.stitches.today
Blinatumomab significantly enhances disease-free survival in children with standard-risk B-cell ALL compared to chemotherapy alone.

by Gupta S, Rau RE (...) Loh ML et 30 al. in N Engl J Med #MedSky

📖 read the article: http://www.nejm.org/doi/10.1056/NEJMoa2411680
March 8, 2025 at 6:28 PM
sorocchungus2.bsky.social
I once worked on a clinical trial looking at potential better treatments for pediatric leukemia. and one wing of the study was so effective they shut down the other wings of study because it unethical to keep them open when this one manner of treatment is provably badass.

Shouts out to blinatumomab
November 21, 2025 at 3:36 AM